Dietary intervention in the management of prostate cancer

Current Opinion in Urology

Volumn 17, Issue 3, 2007, Pages 168-174

  Demark Wahnefried, Wendy ^a   Moyad, Mark M ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Body weight; Diet; Dietary supplements; Nutrition; Prostatic neoplasms

Indexed keywords

ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; LYCOPENE; PLACEBO; SELENIUM; SELENOMETHIONINE;

BODY WEIGHT; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL PRACTICE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIET THERAPY; DRUG DOSE ESCALATION; ENERGY BALANCE; ERECTILE DYSFUNCTION; EXERCISE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; VEGETARIAN DIET; WEIGHT CONTROL;

BODY WEIGHT; CARCINOMA; DIET; DIETARY SUPPLEMENTS; EXERCISE; FOOD; GUIDELINE ADHERENCE; HUMANS; MALE; NUTRITION POLICY; PROSTATIC NEOPLASMS; SURVIVORS;

EID: 34247128748     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3280eb10fc     Document Type: Review

References (44)

1. Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106:581-588.
2. Bassett WW, Cooperberg MR, Sadetsky N, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urol 2005; 66:1060-1065.
3. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24:3979-3983. This cross-sectional study compares biomarkers associated with metabolic syndrome in 20 men undergoing androgen-deprivation therapy for CaP, with 18 age-matched men with nonmetastatic CaP and 20 age-matched controls.
4. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Contr 2006; 17:5-9. This review synthesizes findings related to body weight status and CaP. It offers thoughtful analyses for explaining the conundrum of why obesity is unassociated with CaP incidence, but associated with disease progression and survival.
5. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005; 174:919-922.
6. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol 2005; 174:1798-1801.
7. Freedland SJ, Platz EA, Presti JC Jr, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006; 175:500-504.
8. Freedland SJ, Sokoll LJ, Platz EA, et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 2005; 174:1266-1270.
9. Gade-Andavolu R, Cone LA, Shu S, et al. Molecular interactions of leptin and prostate cancer. Cancer J 2006; 12:201-206.
10. Montgomery JS, Gayed BA, Hollenbeck BK, et al. Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. J Urol 2006; 176:257-261.
11. Mulholland TL, Huynh PN, Huang RR, et al. Urinary incontinence after radical retropubic prostatectomy is not related to patient body mass index. Prostate Cancer Prostatic Dis 2006; 9:153-159.
12. Ribeiro R, Lopes C, Medeiros R. The link between obesity and prostate cancer: the leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 2006; 9:19-24.
13. Siddiqui SA, Inman BA, Sengupta S, et al. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer 2006; 107:521-529. This study exploring the association between BMI and disease-free and overall survival is on a cohort of 5313 men who underwent a radical prostatectomy at the Mayo Clinic and who were followed for a median of 10.1 years.
14. Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 2006; 107:631-639. This retrospective study investigated both biochemical and clinical failure as a function of BMI and was performed on 873 men who received external beam radiotherapy as a sole treatment for localized CaP at MD Anderson and who were followed for a median of 8 years.
15. Strom SS, Wang X, Pettaway CA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 2005; 11:6889-6894.
16. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 1998; 68:899-917.
17. Freedland SJ, Isaacs WB, Mangold LA, et al. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res 2005; 11:2883-2888.
18. Boulos DL, Groome PA, Brundage MD, et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer 2006; 106:1804-1814.
19. Doyle C, Kushi LH, Byers T, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 2006; 56:323-353. The ACS regularly assembles a panel of experts to review the literature related to diet and exercise and its role in the primary prevention of cancer, as well as its importance for cancer control and tertiary prevention among cancer survivors. This report reviews diet and exercise studies related to a spectrum of cancer survivors (including CaP survivors) and issues guidelines for informed choices.
20. Chan JM, Holick CN, Leitzmann MF, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Contr 2006; 17:199-208. This study explores associations between diet (before and after diagnosis) and progressive CaP among the 1202 men diagnosed with this disease in the Health Professionals Follow-up study.
21. Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev 2001; 23:87-92.
22. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 2006; 63:534-546.
23. Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 2005; 23:56-64.
24. Food and Nutrition Board/National Academy of Sciences/Institutes of Medicine. Dietary reference intakes. http://www.iom.edu/Object.File/Master/21/ 372/0.pdf. [Accessed 17 January 2007]
25. Kristal AR, Chi C, Tangen CM, et al. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006; 106:320-328.
26. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98:451-459.
27. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005; 174:1065-1070.
28. Daubenmier JJ, Weidner G, Marlin R, et al. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urol 2006; 67:125-130.
29. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005; 97:94-102.
30. Kirsh VA, Hayes RB, Mayne ST, et al. Supplemental and dietary vitamin E, beta carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006; 98:245-254.
31. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37-46.
32. Bairati I, Meyer F, Jobin E, et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer 2006; 119:2221-2224. This is one of the largest trials in conventional medicine to explore the combination of high-dose antioxidants with standard treatment for cancer. The adverse impact of the combination should encourage clinicians to reduce most if not all supplements during radiation therapy for CaP until more research is completed.
33. Etminan M, FitzGerald JM, Gleave M, et al. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Contr 2005; 16:1125-1131.
34. Sabichi AL, Lee JJ, Taylor RJ, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 2006; 12 (7 Pt 1):2178-2184.
35. See KA, Lavercombe PS, Dillon J, Ginsberg R. Accidental death from acute selenium poisoning. Med J Austral 2006; 185:388-389.
36. Clark PE, Hall MC, Borden LS Jr, et al. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 2006; 67:1257-1261. Results of this small trial suggest that doses of lycopene from 15-120 mg per day, were not associated with detectable changes in PSA doubling time.
37. Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001; 10:861-868.
38. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. Br J Urol Int 2003; 92:375-378.
39. Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol 2004; 22:415-420.
40. Schulman SP, Becker LC, Kass DA, et al. L-Arginine therapy in acute myocardial infarction: the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295:58-64. L-arginine has been promoted for resolution of erectile dysfunction, but when tested in patients with cardiovascular disease, it caused an increased rate of mortality and this trial was abruptly discontinued.
41. National Cancer Institute/Office of Cancer Survivorship. http://cancercontrol.cancer.gov/ocs/prevalence/index.html. [Accessed 21 December 2006]
42. Demark-Wahnefried W, Aziz N, Rowland J, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005; 23:5814-5830.
43. Jones LW, Demark-Wahnefried W. Diet, exercise, and related forms of complementary therapies following primary treatment for cancer. Lancet Oncol 2006; 7:1017-1026.
44. Demark-Wahnefried W, Clipp EC, Morey MC, et al. A lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from project LEAD (Leading the Way in Exercise And Diet). J Clin Oncol 2006; 24:3465-3473.